AstraZeneca Wins Ruling Upholding Key Patent for Diabetes Drug
- Zydus conceded infringement to focus on validity at trial
- Diabetes drug had U.S. sales of $569 million in 2020
Photographer: Jason Alden/Bloomberg
This article is for subscribers only.
AstraZeneca Plc won a federal court ruling upholding a key patent for its diabetes drug Farxiga, staving off threats from cheaper versions.
A trial without a jury in May centered on the validity of a patent that covers Farxiga’s active ingredient, dapagliflozin, its combination with a carrier and methods of treatment. Zydus Cadila conceded infringement before the trial, a common tactic that allowed it to focus on arguments that the patent, which expires in October 2025, wasn’t valid.